CG Oncology announced positive Phase 3 trial results for cretostimogene grenadenorepvec, a monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The trial showed a 75.5% complete response rate with a median response duration of 27.9 months, and about 89% of patients preserved their bladders at 12 months. The treatment demonstrated a favorable safety profile with no severe adverse events and a low progression rate to muscle-invasive cancer. If approved, cretostimogene could become a key bladder-sparing therapy, improving outcomes for patients who have limited options after BCG failure.
Pepeto's crypto presale is rapidly selling out, raising over $10.398 million despite a challenging market, signaling strong investor interest. This surge coincides with Solana's price recovery to $81 and optimistic forecasts of $500 in 2026, highligh...
James Altucher projects that Elon Musk's humanoid robot, dubbed "A.R.M.," could surpass Amazon's $600 billion annual revenue by producing up to 10 million units yearly. Priced between $20,000 and $30,000 each, initial production of 1 million robots c...
Roblox has reduced its guided bookings forecast by as much as 18% and withdrawn its full-year financial outlook. This adjustment is linked to a deliberate change in the platform's algorithm, which has impacted user engagement and revenue projections....
James Altucher, a tech investor, argues Tesla is no longer just a car company but has pivoted to focus on artificial intelligence and robotics. He highlights Tesla's new project called 'A.R.M.,' an AI-powered humanoid robot, which Elon Musk envisions...
Brunswick Corporation has released materials from its 2026 Investor Day, including a recorded strategy presentation, slides, and transcript, available on its website. The presentation details Brunswick's long-term growth strategy, strategic prioritie...
